MRIdian’s clinical and research experience showcased in nearly 40 abstracts at ESTRO 2022, Europe’s leading radiation oncology congress

ViewRay celebrates 10 years as the first and only company to offer real-time tissue tracking with automatic beam triggering and will host a symposium luncheon highlighting new MRIdian A3i features

CLEVELAND, May 6, 2022 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) today announced that the company’s MRIdian MRI-guided radiation therapy system will be featured at the annual meeting of the European Society of Radiation Therapy and Oncology (ESTRO ), with nearly 40 presentations and posters showcasing the clinical and research experience of MRIs. This year’s ESTRO meeting will take place May 6-10, 2022 online and in person in Copenhagen, Denmark.

MRIdian-focused presentations and posters, submitted by MRIdian clinical teams around the world and accepted into ESTRO Scientific Sessions, highlight the clinical value of MRIdian in treating a wide variety of cancers, including pancreas, prostate, liver, rectum, cervix and central/ultracentral lung tumors. Other topics covered include patient satisfaction, cost/benefit analysis and one-day MRI treatments.

On Friday, May 6 to 12:30 p.m. CEST GenesisCare will host a symposium titled “A Revolution Guided by MR”, featuring MRI users from GenesisCare, Amsterdam UMC, Miami Cancer Institute, University Hospital Munich, Moffit Cancer Center and UCLA discuss innovations in MR-guided radiotherapy and its usefulness in lung, gastrointestinal and urological cancers. The event will take place in person at the Admiral Hotel in Copenhagen and streamed live for virtual attendees. Registration available at

MRIdian A3i* is ViewRay’s 4th generation of real-time tissue tracking with automatic beam triggering, now paired with new treatment delivery capabilities focused on improving the efficiency of tabletop adaptive workflow and expanding clinical utility. ViewRay will organize a lunch symposium on Saturday May 7 from 1:00-2:00 p.m. CEST in Hall D1 titled “MRIdian A3i* – ViewRay’s Latest Innovations in MR-Guided RT”. The presentation, which will be given by Drs. Frank Lagerward, Miguel Palacios (Amsterdam UMC), and Drew Moghanaki (UCLA).

This symposium will highlight MRIdian A3i features including MR imaging sequences, automated workflow steps, automatic benchtop contouring tools, multiplanar tissue tracking, and automated beam synchronization, as well as ability of clinicians to work collaboratively during patient treatments. The symposium will also discuss ViewRay’s new brain processing package.

This month brands 10 years since ViewRay introduced real-time tissue tracking with automatic beam triggering. To date, MRIdian customers have treated over 21,000 patients using this feature on over 200,000 fractions. MRIdian remains the first and only system to offer real-time tissue tracking with automatic beam synchronization.

Visitors to ViewRay’s booth #1050 can also see demonstrations and presentations of MRIdian A3i* and the new brain processing package. They can also hear first-hand experience from clinicians around the world highlighting the benefits of MRIdian in treating various cancers, including:

Saturday May 7

  • SMART MRI scanner for lung cancer: Dr. Stephen RosenbergMoffitt Cancer Center
  • MRIdian SMART for the treatment of Lattice in liver: Dr. Enis Özyar, Acibadem Maslak Hospital

Sunday May 8

  • SMART MRI for oligometastatic cancer: Dr. Lauren Henke, University of Washington
  • SMART MRI scanner for the heart: Dr. Luca BoldriniGemelli
  • Synthetic CT with MRI images: Dr. David CusumanoMater Olbia Hospital

Monday May 9

  • MRI solutions for pancreatic cancer: Dr. Michael ChuongMiami Cancer Institute
  • MRIdian SMART for Liver SABR: Dr Agnès Tallet, Paoli-Calmettes Institute, Marseilles
  • MRI solutions for prostate cancer: Dr. Philippe CamilleriGenesisCare Oxford

Over 21,000 patients have been treated with MRIdian. Currently, 50 MRI systems are installed in hospitals around the world where they are used to treat a wide variety of solid tumors and are the subject of many ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. For a list of treatment centers, please visit:

* MRIdian A3i features are only for sale in the United States, and the information contained herein regarding these features is for demonstration purposes only and may not be offered for sale until applicable regulations are met .

The opinions and clinical experiences discussed herein are specific to the physicians featured and are for informational purposes only. Nothing in this document is intended to provide specific medical advice or to replace written law or regulation. The treatment results presented in this press release are not indicative of typical or future results.

Security statement
The MRIdian Linac system is not suitable for all patients, including those who are not candidates for magnetic resonance imaging. Radiation therapies can cause side effects that can vary depending on the part of the body being treated. The most common are usually temporary and may include, but are not limited to, irritation of the respiratory, digestive, urinary, or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be serious. Treatment sessions can vary in complexity and duration. Radiation therapy is not appropriate for all cancers. You should discuss the potential for side effects and their severity and the benefits of radiation therapy and magnetic resonance imaging with your doctor to make sure radiation therapy is right for you.

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures and markets the MRIdian® MRI-guided radiation therapy system. MRIdian is built on a proprietary high-definition MR imaging system designed from the ground up to meet the unique challenges and clinical workflow of advanced radiation oncology. Unlike MRI systems used in diagnostic radiology, MRIdian’s high-definition MRI has been specifically designed to address specific challenges including beam distortion, skin toxicity, and other issues that can arise when high magnetic fields interact with beams of radiation. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, among other things, ViewRay’s financial forecast for the full year 2022, expected future orders, expected future operational and financial performance, treatment outcomes, therapy uptake, innovation and performance of MRIdian systems. Actual results could differ from those projected in the forward-looking statements due to many factors. These factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay’s products, ability to convert backlog into revenue, timing of delivery of ViewRay’s products, timing, and the severity of the COVID-19 pandemic, including its impacts on our business on demand, our operations and our global supply chains, supply disruptions or changes in the costs of raw materials, labor labor, product components or transportation services due to inflation, results and other uncertainties associated with testing, the ability to raise additional funds necessary to continue to pursue business and product development plans of ViewRay, the inherent uncertainties associated with the development of new products or technologies, competition in the industry in which ViewRay operates and the general market conditions. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business generally, see ViewRay’s current and future reports filed with of the Securities and Exchange Commission, including its annual report on Form 10-K for the fiscal year ended December 31, 2021 and its quarterly reports on Form 10-Q, updated periodically along with the company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay undertakes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. , except as required by law.

View original content: – meeting-radiotherapy-oncology-301541244.html

SOURCE ViewRay, Inc.

Comments are closed.